Video

Ty Gluckman, MD: Cardiovascular Concerns in 2022

Author(s):

There is concern for cardiovascular patients over missed screenings during the pandemic.

One of the long-term impact of the COVID-19 pandemic is cardiovascular concerns.

With many gyms closed, activities cancelled, and people picking up poor habits

In an interview with HCPLive® during Pri-Med West 2022 in Anaheim, Ty Gluckman, MD, Medical Director of the Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS), explained how the pandemic may have resulted in an increase in bad cholesterol results for many.

Gluckman said there is legitimate concern over patients comining in with higher cholesterol because of the bad habits they picked up during the pandemic in regard to food, alcohol, and a lack of exercise.

“It was very sobering to see that year over year increases in both systolic and dystolic blood pressures have gone up, rates of obesirty have gone up,” Gluckman said. “So it is absolutely no question that that access to a lot services has played a role and access to clinicians, especially early on in the pandemic, has created challenges.”

Another concern is the severity of disease.

Many patients did forego appointments and screenings during the initial part of the pandemic due fear of catching COVID-19 in a hospital setting.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
© 2024 MJH Life Sciences

All rights reserved.